Factor XIII Treatment & Management

  • Author: Robert A Schwartz, MD, MPH; Chief Editor: Emmanuel C Besa, MD   more...
 
Updated: Mar 25, 2011
 

Medical Care

FXIII replacement is used to treat bleeding, to prevent perioperative bleeding during elective surgical procedures or, prophylactically, to prevent recurrent bleeding, as in CNS or joint hemorrhages. Serial monitoring of achieved FXIII levels is essential to document the adequacy of any therapy.

Prompt and adequate therapy for acute bleeding is essential along with immobilization of the affected sites and pain relief. Most patients receive FFP or cryoprecipitate to treat bleeding. Information regarding the amount of FXIII present in either of these products usually is not available; therefore, monitoring the adequacy of FXIII levels is essential.

Two intermediate-purity FXIII concentrates are being tested in the United States and are available in other countries. Note the following:

  • Virus-inactivated FXIII concentrates made from human plasma or placenta are an improvement over traditional products.
  • Human factor XIII concentrate (Corifact by CSL Behring) is now approved as an orphan drug in the United States. The brand name Fibrogammin P (CLS Behring) is the plasma-derived virus-inactivated concentrate marketed in Europe, South America, South Africa, and Japan. A second FXIII concentrate (Bio Products Laboratory, Elstree, Hertfordshire, UK) is available on a per patient request.
  • No rFXIII product is currently commercially available in the United States.

The long half-life of FXIII of 6-19 days and the hemostatic efficacy of even small amounts of FXIII of approximately 5% allow replacement therapy to be administered every 4-6 weeks. An FFP dose of 2-3 mL/kg may be effective for up to 4 weeks.[94, 95] The dose of concentrate in adults with deficiency is 35 U/kg every 4 weeks.[96, 97, 98]

A paucity of data exists concerning the pediatric population. Hemostatic evaluation following a head trauma-induced large subcutaneous hematoma associated with recurrent postsurgical bleeding led to a diagnosis of severe FXIII deficiency in a 22-month-old boy. Following initial therapy, subsequent replacement with an FXIII concentrate dose of 50 U/kg every 5 weeks was sufficient to prevent rebleeding and allow healing.[99] Serial monitoring of actual levels achieved is important in children to determine adequacy of any therapy.

Minor bleeding, as from cuts and abrasions, may respond to conservative measures, such as pressure, ice, and use of antifibrinolytic drugs. Avoidance of trauma and nonsteroidal anti-inflammatory drugs (NSAIDs) is helpful in reducing bleeding events.

Several reports exist of the use of FXIII in unusual circumstances. Note the following:

  • Effectiveness of normalizing FXIII levels in the treatment of a cerebrospinal fluid leak, which started 2 weeks after removal of a meningioma, was reported in a Japanese patient.[100]
  • The potential use of transglutaminases to mechanically stabilize and allow cultured epithelial autografts to take when used to repair extensive skin wounds supports a possible role of FXIII in the formation of de novo dermoepidermal junctions, thereby facilitating permanent skin replacement.[100]
  • Improved stability of surgical wounds has been reported following infusion of FXIII concentrates.
  • Although a few reports exist concerning the use of FXIII replacement in patients with scleroderma, Henoch-Schönlein purpura, and malignancies, the value of such replacement therapy remains to be established by proper clinical trials.[6, 101, 102, 103]

Patients with acquired inhibitors to FXIII should be treated using well-established principles of therapy. Note the following:

  • FXIII dose depends on the characteristics of the inhibitor. One patient was treated preoperatively using a 10-fold dose of FXIII concentrate (350 U/kg) followed by a similar postoperative dose resulting in adequate hemostasis after coronary bypass graft surgery.[98]
  • In addition to administering an FXIII concentrate whenever available, treat the underlying disorder and, when appropriate, use immunosuppressive agents, including the newer B-cell-directed monoclonal antibodies.
  • Note that spontaneous disappearance of acquired inhibitors is part of their natural history, and the use of milder less toxic immunomodulators, such as steroids, may suffice.
  • The proper choice of agent is dictated by clinical circumstances. Simple immediate ancillary measures of ice, pressure, ace wrap, immobilization of the affected joint, and avoidance of NSAIDs must not be forgotten.
  • The complexity of required treatment is exemplified by a patient with an INH-induced inhibitor in whom INH was discontinued, cryoprecipitate and FXIII concentrate were administered, the patient underwent plasma exchanges and treatment with an immunoadsorption column to reduce the inhibitor's titer, and immunosuppressives were administered before hemostatic success was achieved.[83, 81, 85]

To date, prophylactic factor replacement has been undertaken mainly in patients with intracranial bleeding or recurrent miscarriages caused by severe FXIII deficiency. Successful prevention of recurrent joint bleeds also has been accomplished using periodic transfusions of FFP and cryoprecipitate.[63] FFP can be administered in a dose of 2-3 mL/kg every 4 weeks.

A literature review of bleeding risks and reproduction among patients with severe FXIII deficiency suggests that patients with clinically significant bleeding should start receiving factor replacement therapy in childhood to reduce early mortality from hemorrhages and to allow patients to reach adulthood. During pregnancy, monthly replacement was found to be effective in preventing miscarriages.[104] However, both short-term benefits and potential long-term adverse consequences of prophylactic use of these products must be discussed, with full patient participation in all decision making.

Advances in the types of available products improve care. Addition of Tween 20 makes a reduction of the generation of soluble and insoluble aggregates of rFXIII possible when rFXIII is subjected to freezing and thawing or agitation.[105] Another advance in the technology relates to solving problems faced during freeze-drying and storing the dry solid. Improvement in storage stability of therapeutic proteins has obvious advantages for both storage and transport.[106]

Pooled plasma treated with solvent-detergent (PLAS+SD) is available to treat any condition in which FFP typically is used and for which no factor concentrate is available. Viral inactivation using the solvent-detergent (SD) process has been used in preparation of coagulation factor concentrates in the past. In vitro treatment of donor plasma with 1% of the solvent tri(n- butyl) phosphate (TNBP) and 1% of the detergent Triton X-100 leads to significant inactivation of a broad spectrum of lipid-enveloped viruses. Note the following:

  • Studies of viral inactivation using the SD process show significant inactivation of the human pathogenic viruses hepatitis B and C and HIV. Other lipid-enveloped viruses (eg, Sindbis virus, bovine viral diarrhea virus) also have been used to monitor inactivation.
  • PLAS+SD is ABO blood type specific, and SD-treated plasma should be ABO compatible with the recipient's red cells.
  • The frozen product is supplied in 200-mL bags. Each 200-mL bag has been demonstrated to raise factor levels by approximately 2-3%, with 4-6 bags raising the factor level of a 70-kg person by approximately 8-18%.
  • Monitoring of specific factor levels before and after product infusion is important to ensure that hemostatically adequate levels are achieved and maintained to provide adequate hemostasis.

Antifibrinolytic agents are not used commonly to treat patients with FXIII deficiency but may be used as ancillary therapy. Note the following:

  • The hemostatic plug formed in the presence of adequate levels of FXIII at the time of surgical trauma (as with dental procedures or with mucosal bleeding) can be preserved by inhibiting fibrinolysis with ε -aminocaproic acid (EACA; Amicar) or trans-p- aminomethyl-cyclohexane carboxylic acid (AMCA; also termed tranexamic acid; Cyklokapron) administered orally or, if needed, intravenously. EACA has been administered in a dose of 5 g orally or intravenously slowly prior to the surgical procedure, along with a dose of the appropriate FXIII replacement. This is followed by a maintenance dose of 1 g/h postoperatively until it is appropriate to start tapering the dose over the next several days.
  • AMCA is administered in a dose of 1.5 g intravenously every 6-8 hours and tapered, as needed; however, it is not available in the United States.
  • Antifibrinolytic agents also can be used as a mouthwash for oral bleeding and have been used to stop local intracavitary oozing.
  • Antifibrinolytic agents are contraindicated in patients with hematuria because of the possible risk of development of a firm occluding clot in the ureters when administered simultaneously with factor replacement. The drugs are not useful in the treatment of joint bleeding (see Factor VIII for more information).

In recent years, the use of NSAIDs to relieve pain has increased in patients with bleeding disorders. Although they provide relief from inflammatory pain, patients experience increased GI tract or other bleeding because of the impact of the drugs on primary hemostasis, and they require additional FXIII replacement to control bleeding. The problem is magnified by the availability of over-the-counter NSAID pain relievers. Non-NSAIDs, such as acetaminophen and codeine-type analgesics, are much less effective, and some are addictive.

Routine dental care is of the utmost importance in maintaining dental hygiene.

Other routine care, such as mammography in women older than 50 years or colonoscopy for patients older than 50 years, must be provided as in nonbleeding patients.

Next

Surgical Care

All elective procedures require proper perioperative management. Note the following:

  • Patients with severe FXIII deficiency require FXIII replacement both preoperatively and postoperatively. Levels of as little as 3-5% may be sufficient to provide adequate hemostasis, and a single dose is sufficient to last several weeks unless excessive blood loss occurs. Serial factor levels must be performed to ensure adequacy of FXIII levels.
  • Procedures such as endoscopies, although considered routine for unaffected individuals, require preprocedural product replacement so that patients do not bleed during or following a needed biopsy. Postbiopsy replacement must continue until the biopsy site has healed.
  • Dental extractions or mucosal procedures can be handled using a single preprocedure dose of FXIII along with Amicar or AMCA. A standardized approach to dental extractions, as has been proposed for patients with hemophilia, may be used in patients with FXIII deficiency. Continuing antifibrinolytics on an outpatient basis for several days after a dental extraction is routine practice, with gradual tapering of dosage.
  • Avoidance of NSAIDs and other platelet-inhibiting drugs perioperatively is essential to minimize bleeding risk. Ice packs and pressure are always useful when feasible.
  • Application of fibrin glue as an ancillary measure is useful in helping control bleeding at surgical sites. Fibrin glue consists of a mixture of fibrinogen, thrombin, and FXIII used to cross-link freshly formed fibrin. Cryoprecipitate also has been used as a source of fibrinogen and FXIII, with the use of bovine thrombin to clot fibrinogen. Some preparations also incorporate antifibrinolytic agents to prevent clot lysis. In particular, fibrin glue has been useful in orthopedic surgery and with surgical procedures in patients with FXIII inhibitors. Bovine thrombin may elicit antibodies.
  • Bleeding from suture holes is a complication in a variety of invasive vascular procedures (surgery, radiologic procedure, coronary angiography). In an experimental porcine vascular graft model, fibrin sealant containing FXIII effectively reduced blood loss and reduced the time to achieve adequate hemostasis more than fibrin alone or thrombin-coated gelatin sponges.[107]
Previous
Next

Consultations

A hematologist, orthopedist, physical therapist, dentist, social worker, psychologist, infectious disease specialist, gastroenterologist/hepatologist, geneticist, and an appropriately equipped special laboratory all play important roles in providing optimal care for patients with FXIII deficiency and their families.

The efforts of the National Hemophilia Foundation and its regional chapters must be recognized in helping to educate patients, assist service providers, foster dialog regarding problems and solutions among patients with bleeding disorders, and improve conditions for the entire community through support of legislation.

Previous
Next

Diet

A healthy and nutritional diet should be encouraged.

Previous
Next

Activity

Appropriate physical activity and physical therapy must be encouraged to maintain and preserve muscle function.

Previous
Proceed to Medication
 
 
Contributor Information and Disclosures
Author

Robert A Schwartz, MD, MPH  Professor and Head, Dermatology, Professor of Pathology, Pediatrics, Medicine, and Preventive Medicine and Community Health, University of Medicine and Dentistry of New Jersey-New Jersey Medical School

Robert A Schwartz, MD, MPH is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American College of Physicians, and Sigma Xi

Disclosure: Nothing to disclose.

Coauthor(s)

Elzbieta Klujszo, MD  Head of Department of Dermatology, Wojewodzki Szpital Zespolony, Kielce

Disclosure: Nothing to disclose.

Pere Gascon, MD, PhD  Professor and Director, Division of Medical Oncology, Institute of Hematology and Medical Oncology, IDIBAPS, University of Barcelona Faculty of Medicine, Spain

Pere Gascon, MD, PhD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians, New York Academy of Medicine, New York Academy of Sciences, and Sigma Xi

Disclosure: Nothing to disclose.

Rajalaxmi McKenna, MD, FACP  Southwest Medical Consultants, SC, Department of Medicine, Good Samaritan Hospital, Advocate Health Systems

Rajalaxmi McKenna, MD, FACP is a member of the following medical societies: American Society of Clinical Oncology, American Society of Hematology, and International Society on Thrombosis and Haemostasis

Disclosure: Nothing to disclose.

Specialty Editor Board

Paul Schick, MD  Emeritus Professor, Department of Internal Medicine, Jefferson Medical College of Thomas Jefferson University; Research Professor, Department of Internal Medicine, Drexel University College of Medicine; Adjunct Professor of Medicine, Lankenau Hospital

Paul Schick, MD is a member of the following medical societies: American College of Physicians, American Heart Association, American Society of Hematology, International Society on Thrombosis and Haemostasis, and New York Academy of Sciences

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Ronald A Sacher, MB, BCh, MD, FRCPC  Professor, Internal Medicine and Pathology, Director, Hoxworth Blood Center, University of Cincinnati Academic Health Center

Ronald A Sacher, MB, BCh, MD, FRCPC is a member of the following medical societies: American Association for the Advancement of Science, American Association of Blood Banks, American Clinical and Climatological Association, American Society for Clinical Pathology, American Society of Hematology, College of American Pathologists, International Society of Blood Transfusion, International Society on Thrombosis and Haemostasis, and Royal College of Physicians and Surgeons of Canada

Disclosure: Glaxo Smith Kline Honoraria Speaking and teaching; Talecris Honoraria Board membership

Rebecca J Schmidt, DO, FACP, FASN  Professor of Medicine, Section Chief, Department of Medicine, Section of Nephrology, West Virginia University School of Medicine

Rebecca J Schmidt, DO, FACP, FASN is a member of the following medical societies: American College of Physicians, American Medical Association, American Society of Nephrology, International Society of Nephrology, National Kidney Foundation, Renal Physicians Association, and West Virginia State Medical Association

Disclosure: Renal Ventures Ownership interest Other

Chief Editor

Emmanuel C Besa, MD  Professor, Department of Medicine, Division of Hematologic Malignancies, Kimmel Cancer Center, Jefferson Medical College of Thomas Jefferson University

Emmanuel C Besa, MD is a member of the following medical societies: American Association for Cancer Education, American College of Clinical Pharmacology, American Federation for Medical Research, American Society of Clinical Oncology, American Society of Hematology, and New York Academy of Sciences

Disclosure: Nothing to disclose.

References

  1. Laki K, Lóránd L. On the Solubility of Fibrin Clots. Science. Sep 10 1948;108(2802):280. [Medline].

  2. Duckert F, Jung E, Sherling DH. An undescribed congenital haemorrhagic diathesis probably due to fibrin stabilizing factor deficiency. Thromb Diath Haemorrh. 1960;5:179.

  3. Duckert F. Documentation of the plasma factor XIII deficiency in man. Ann N Y Acad Sci. Dec 8 1972;202:190-9. [Medline].

  4. Laki K. Our ancient heritage in blood clotting and some of its consequences. Ann N Y Acad Sci. Dec 8 1972;202:297-307. [Medline].

  5. Reitsma PH. Genetic principles underlying disorders of procoagulant and anticoagulant proteins. In: Coleman RW, Hirsh J, Marder VJ, et al, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia, Pa: Lippincott Williams & Wilkins; 2001:59-87.

  6. Loewy AG, McDonagh J, Mikkola H, et al. Structure and function of F XIII. In: Coleman RW, Hirsh J, Marder VJ, et al, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia, Pa: Lippincott Williams & Wilkins; 2001:233-48.

  7. Cushman M, O'Meara ES, Folsom AR, Heckbert SR. Coagulation factors IX through XIII and the risk of future venous thrombosis: the Longitudinal Investigation of Thromboembolism Etiology. Blood. Oct 1 2009;114(14):2878-83. [Medline]. [Full Text].

  8. Hoppe B, Tolou F, Dörner T, Kiesewetter H, Salama A. Gene polymorphisms implicated in influencing susceptibility to venous and arterial thromboembolism: frequency distribution in a healthy German population. Thromb Haemost. Oct 2006;96(4):465-70. [Medline].

  9. Wells PS, Anderson JL, Rodger MA, Carson N, Grimwood RL, Doucette SP. The factor XIII Val34Leu polymorphism: is it protective against idiopathic venous thromboembolism?. Blood Coagul Fibrinolysis. Oct 2006;17(7):533-8. [Medline].

  10. Shafey M, Anderson JL, Scarvelis D, Doucette SP, Gagnon F, Wells PS. Factor XIII Val34Leu variant and the risk of myocardial infarction: a meta-analysis. Thromb Haemost. Apr 2007;97(4):635-41. [Medline].

  11. Shin JI, Lee JS. Severe gastrointestinal vasculitis in Henoch-Schoenlein purpura: pathophysiologic mechanisms, the diagnostic value of factor XIII, and therapeutic options. Eur J Pediatr. Nov 2007;166(11):1199-200; author reply 1201. [Medline].

  12. Shin JI, Lee JS. Could measurement of factor XIII level detect the vasculitic process of Henoch-Schönlein purpura without skin rash?. Acta Paediatr. Apr 2008;97(4):395. [Medline].

  13. Kuroda K, Tajima S. Proliferation of HSP47-positive skin fibroblasts in dermatofibroma. J Cutan Pathol. Jan 2008;35(1):21-6. [Medline].

  14. Ivaskevicius V, Biswas A, Loreth R, et al. Mutations affecting disulphide bonds contribute to a fairly common prevalence of F13B gene defects: results of a genetic study in 14 families with factor XIII B deficiency. Haemophilia. Mar 10 2010;[Medline].

  15. Lorand L. Factor XIII: structure, activation, and interactions with fibrinogen and fibrin. Ann N Y Acad Sci. 2001;936:291-311. [Medline].

  16. Siebenlist KR, Meh DA, Mosesson MW. Plasma factor XIII binds specifically to fibrinogen molecules containing gamma chains. Biochemistry. Aug 13 1996;35(32):10448-53. [Medline].

  17. Greenberg CS, Shuman MA. The zymogen forms of blood coagulation factor XIII bind specifically to fibrinogen. J Biol Chem. Jun 10 1982;257(11):6096-101. [Medline].

  18. Mosesson M. Hereditary abnormalities of fibrinogen. In: Beutler E, Lichtman M, Coller BS, et al, eds. Williams Hematology. New York, NY: McGraw-Hill; 2001:1659-71.

  19. Jenner L, Husted L, Thirup S, Sottrup-Jensen L, Nyborg J. Crystal structure of the receptor-binding domain of alpha 2-macroglobulin. Structure. May 15 1998;6(5):595-604. [Medline].

  20. Nagy B Jr, Simon Z, Bagoly Z, Muszbek L, Kappelmayer J. Binding of plasma factor XIII to thrombin-receptor activated human platelets. Thromb Haemost. Jul 2009;102(1):83-9. [Medline].

  21. Monteiro MR, Murphy EE, Galaria NA, Whitaker-Menezes D, Murphy GF. Cytological alterations in dermal dendrocytes in vitro: evidence for transformation to a non-dendritic phenotype. Br J Dermatol. Jul 2000;143(1):84-90. [Medline].

  22. Lorand L. Sol Sherry Lecture in Thrombosis : research on clot stabilization provides clues for improving thrombolytic therapies. Arterioscler Thromb Vasc Biol. Jan 2000;20(1):2-9. [Medline].

  23. Noguchi K, Ishikawa K, Yokoyama Ki, Ohtsuka T, Nio N, Suzuki E. Crystal structure of red sea bream transglutaminase. J Biol Chem. Apr 13 2001;276(15):12055-9. [Medline].

  24. Andersen MD, Kjalke M, Bang S, et al. Coagulation factor XIII variants with altered thrombin activation rates. Biol Chem. Dec 2009;390(12):1279-83. [Medline].

  25. Fox BA, Yee VC, Pedersen LC, et al. Identification of the calcium binding site and a novel ytterbium site in blood coagulation factor XIII by x-ray crystallography. J Biol Chem. Feb 19 1999;274(8):4917-23. [Medline].

  26. Casadio R, Polverini E, Mariani P, et al. The structural basis for the regulation of tissue transglutaminase by calcium ions. Eur J Biochem. Jun 1999;262(3):672-9. [Medline].

  27. Hevessy Z, Haramura G, Boda Z, Udvardy M, Muszbek L. Promotion of the crosslinking of fibrin and alpha 2-antiplasmin by platelets. Thromb Haemost. Jan 1996;75(1):161-7. [Medline].

  28. Moaddel M, Falls LA, Farrell DH. The role of gamma A/gamma ' fibrinogen in plasma factor XIII activation. J Biol Chem. Oct 13 2000;275(41):32135-40. [Medline].

  29. Weiss MS, Metzner HJ, Hilgenfeld R. Two non-proline cis peptide bonds may be important for factor XIII function. FEBS Lett. Feb 27 1998;423(3):291-6. [Medline].

  30. Jámbor C, Reul V, Schnider TW, Degiacomi P, Metzner H, Korte WC. In vitro inhibition of factor XIII retards clot formation, reduces clot firmness, and increases fibrinolytic effects in whole blood. Anesth Analg. Oct 2009;109(4):1023-8. [Medline].

  31. Lorand L, Urayama T, Atencio AC, Hsia DY. Inheritance of deficiency of fibrin-stabilizing factor (factor 13). Am J Hum Genet. Jan 1970;22(1):89-95. [Medline]. [Full Text].

  32. Anwar R, Gallivan L, Edmonds SD, Markham AF. Genotype/phenotype correlations for coagulation factor XIII: specific normal polymorphisms are associated with high or low factor XIII specific activity. Blood. Feb 1 1999;93(3):897-905. [Medline].

  33. Kangsadalampai S, Board PG. The Val34Leu polymorphism in the A subunit of coagulation factor XIII contributes to the large normal range in activity and demonstrates that the activation peptide plays a role in catalytic activity. Blood. Oct 15 1998;92(8):2766-70. [Medline].

  34. Saha N, Aston CE, Low PS, Kamboh MI. Racial and genetic determinants of plasma factor XIII activity. Genet Epidemiol. Dec 2000;19(4):440-55. [Medline].

  35. van Wersch JW, Vooijs ME, Ubachs JM. Coagulation factor XIII in pregnant smokers and non-smokers. Int J Clin Lab Res. 1997;27(1):68-71. [Medline].

  36. Asahina T, Kobayashi T, Okada Y, et al. Studies on the role of adhesive proteins in maintaining pregnancy. Horm Res. 1998;50 Suppl 2:37-45. [Medline].

  37. Asahina T, Kobayashi T, Okada Y, Goto J, Terao T. Maternal blood coagulation factor XIII is associated with the development of cytotrophoblastic shell. Placenta. May 2000;21(4):388-93. [Medline].

  38. Anwar R, Miloszewski KJ. Factor XIII deficiency. Br J Haematol. Dec 1999;107(3):468-84. [Medline].

  39. Noll T, Wozniak G, McCarson K, et al. Effect of factor XIII on endothelial barrier function. J Exp Med. May 3 1999;189(9):1373-82. [Medline]. [Full Text].

  40. Cario E, Goebell H, Dignass AU. Factor XIII modulates intestinal epithelial wound healing in vitro. Scand J Gastroenterol. May 1999;34(5):485-90. [Medline].

  41. Naito M, Nomura H, Iguchi A, Thompson WD, Smith EB. Effect of crosslinking by factor XIIIa on the migration of vascular smooth muscle cells into fibrin gels. Thromb Res. May 1 1998;90(3):111-6. [Medline].

  42. Wozniak G, Noll T, Brunner U, Hehrlein FW. Topical treatment of venous ulcer with fibrin stabilizing factor: experimental investigation of effects on vascular permeability. Vasa. Aug 1999;28(3):160-3. [Medline].

  43. Catani MV, Bernassola F, Rossi A, Melino G. Inhibition of clotting factor XIII activity by nitric oxide. Biochem Biophys Res Commun. Aug 10 1998;249(1):275-8. [Medline].

  44. Bernassola F, Rossi A, Melino G. Regulation of transglutaminases by nitric oxide. Ann N Y Acad Sci. 1999;887:83-91. [Medline].

  45. Huang QQ, Teng MK, Niu LW. Purification and characterization of two fibrinogen-clotting enzymes from five-pace snake (Agkistrodon acutus) venom. Toxicon. Jul 1999;37(7):999-1013. [Medline].

  46. Arocha-Pinango CL, Marval E, Guerrero B. Lonomia genus caterpillar toxins: biochemical aspects. Biochimie. Sep-Oct 2000;82(9-10):937-42. [Medline].

  47. Zavalova L, Lukyanov S, Baskova I, et al. Genes from the medicinal leech (Hirudo medicinalis) coding for unusual enzymes that specifically cleave endo-epsilon (gamma-Glu)-Lys isopeptide bonds and help to dissolve blood clots. Mol Gen Genet. Nov 27 1996;253(1-2):20-5. [Medline].

  48. Undas A, Brummel KE, Musial J, Mann KG, Szczeklik A. Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation. Circulation. May 8 2001;103(18):2248-53. [Medline].

  49. Finney S, Seale L, Sawyer RT, Wallis RB. Tridegin, a new peptidic inhibitor of factor XIIIa, from the blood- sucking leech Haementeria ghilianii. Biochem J. Jun 15 1997;324 ( Pt 3):797-805. [Medline].

  50. Lee SY, Chang SK, Lee IH, Kim YM, Chung SI. Depletion of plasma factor XIII prevents disseminated intravascular coagulation-induced organ damage. Thromb Haemost. Mar 2001;85(3):464-9. [Medline].

  51. Sidelmann JJ, Gram J, Jespersen J, Kluft C. Fibrin clot formation and lysis: basic mechanisms. Semin Thromb Hemost. 2000;26(6):605-18. [Medline].

  52. Takahashi H, Isobe T, Horibe S, et al. Tissue transglutaminase, coagulation factor XIII, and the pro-polypeptide of von Willebrand factor are all ligands for the integrins alpha 9beta 1 and alpha 4beta 1. J Biol Chem. Aug 4 2000;275(31):23589-95. [Medline].

  53. Salge U, Daubner E, Heiden M, Sietz R. Factor XIII does not stimulate growth of human cultured tumor cells. Blood Coagul Fibrinolysis. Mar 2000;11(2):217-8. [Medline].

  54. Molnar P, Nemes Z. Hemangiopericytoma of the cerebello-pontine angle. Diagnostic pitfalls and the diagnostic value of the subunit A of factor XIII as a tumor marker. Clin Neuropathol. Jan-Feb 1995;14(1):19-24. [Medline].

  55. Adany R, Bardos H, Antal M, et al. Factor XIII of blood coagulation as a nuclear crosslinking enzyme. Thromb Haemost. May 2001;85(5):845-51. [Medline].

  56. Kallberg Y, Gustafsson M, Persson B, Thyberg J, Johansson J. Prediction of amyloid fibril-forming proteins. J Biol Chem. Apr 20 2001;276(16):12945-50. [Medline].

  57. Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem. Jun 16 1995;270(24):14477-84. [Medline].

  58. Redlitz A, Tan AK, Eaton DL, Plow EF. Plasma carboxypeptidases as regulators of the plasminogen system. J Clin Invest. Nov 1995;96(5):2534-8. [Medline].

  59. Bajzar L, Nesheim ME, Tracy PB. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. Blood. Sep 15 1996;88(6):2093-100. [Medline].

  60. Hoffman M, Monroe DM 3rd. A cell-based model of hemostasis. Thromb Haemost. Jun 2001;85(6):958-65. [Medline].

  61. HGMD. Human Gene Mutation Database at the Institute of Medical Genetics in Cardiff. Available at: http://www.uwcm.ac.uk//uwcm/mg/hgmd0.html. Accessed April 9, 2002;[Full Text].

  62. Attié-Castro FA, Zago MA, Lavinha J, et al. Ethnic heterogeneity of the factor XIII Val34Leu polymorphism. Thromb Haemost. Oct 2000;84(4):601-3. [Medline].

  63. Thakker S, McGehee W, Quismorio FP Jr. Arthropathy associated with factor XIII deficiency. Arthritis Rheum. Jun 1986;29(6):808-11. [Medline].

  64. Mikkola H, Muszbek L, Laiho E, et al. Molecular mechanism of a mild phenotype in coagulation factor XIII (FXIII) deficiency: a splicing mutation permitting partial correct splicing of FXIII A-subunit mRNA. Blood. Feb 15 1997;89(4):1279-87. [Medline].

  65. Greenberg DL, Davie EW. Blood coagulation factors: their complementary DNAs, genes, and expression. In: Coleman RW, Hirsh J, Marder VJ, et al, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia, Pa: Lippincott Williams & Wilkins; 2001:21-57.

  66. Kangsadalampai S, Yenchitsomanus P, Chelvanayagam G, Sawasdee N, Laosombat V, Board P. Identification of a new mutation (Gly420Ser), distal to the active site, that leads to factor XIII deficiency. Eur J Haematol. Oct 2000;65(4):279-84. [Medline].

  67. Koseki S, Souri M, Koga S, et al. Truncated mutant B subunit for factor XIII causes its deficiency due to impaired intracellular transportation. Blood. May 1 2001;97(9):2667-72. [Medline].

  68. Gomez Garcia EB, Poort SR, Stibbe J. Two novel and one recurrent missense mutation in the factor XIII A gene in two Dutch patients with factor XIII deficiency. Br J Haematol. Feb 2001;112(2):513-8. [Medline].

  69. Anwar R, Gallivan L, Trinh C, Hill F, Markham A. Identification of a new Leu354Pro mutation responsible for factor XIII deficiency. Eur J Haematol. Feb 2001;66(2):133-6. [Medline].

  70. Warner D, Mansfield MW, Grant PJ. Coagulation factor XIII and cardiovascular disease in UK Asian patients undergoing coronary angiography. Thromb Haemost. Mar 2001;85(3):408-11. [Medline].

  71. Canavy I, Henry M, Morange PE, et al. Genetic polymorphisms and coronary artery disease in the south of France. Thromb Haemost. Feb 2000;83(2):212-6. [Medline].

  72. Franco RF, Middeldorp S, Meinardi JR, van Pampus EC, Reitsma PH. Factor XIII Val34Leu and the risk of venous thromboembolism in factor V Leiden carriers. Br J Haematol. Oct 2000;111(1):118-21. [Medline].

  73. Catto AJ, Kohler HP, Coore J, Mansfield MW, Stickland MH, Grant PJ. Association of a common polymorphism in the factor XIII gene with venous thrombosis. Blood. Feb 1 1999;93(3):906-8. [Medline].

  74. Kohler HP. Role of blood coagulation factor XIII in vascular diseases. Swiss Med Wkly. Jan 27 2001;131(3-4):31-4. [Medline].

  75. Prata MJ, Miranda C, Rocha J, Amorim A. Allelic affinities between the F13A common gene products inferred by the analysis of an (AAAG)n STR polymorphism within the 5' untranslated region. Hum Hered. May-Jun 2000;50(3):189-93. [Medline].

  76. Wilmer M, Rudin K, Kolde H, et al. Evaluation of a sensitive colorimetric FXIII incorporation assay. Effects of FXIII Val34Leu, plasma fibrinogen concentration and congenital FXIII deficiency. Thromb Res. Apr 1 2001;102(1):81-91. [Medline].

  77. Hedner U, Ginsburg D, Lusher JM, High KA. Congenital Hemorrhagic Disorders: New Insights into the Pathophysiology and Treatment of Hemophilia. Hematology Am Soc Hematol Educ Program. 2000;241-265. [Medline].

  78. Coukos G, Rubin SC. Gene therapy for ovarian cancer. Oncology (Williston Park). Sep 2001;15(9):1197-204, 1207; discussion 1207-8. [Medline].

  79. Chandler WL, Patel MA, Gravelle L, et al. Factor XIIIA and clot strength after cardiopulmonary bypass. Blood Coagul Fibrinolysis. Mar 2001;12(2):101-8. [Medline].

  80. Holst FG, Hemmer CJ, Foth C, Seitz R, Egbring R, Dietrich M. Low levels of fibrin-stabilizing factor (factor XIII) in human Plasmodium falciparum malaria: correlation with clinical severity. Am J Trop Med Hyg. Jan 1999;60(1):99-104. [Medline].

  81. Lorand L, Velasco PT, Murthy SN, Lefebvre P, Green D. Autoimmune antibody in a hemorrhagic patient interacts with thrombin-activated factor XIII in a unique manner. Blood. Feb 1 1999;93(3):909-17. [Medline].

  82. Feinstein DI. Immune coagulation disorders. In: Coleman RW, Hirsh J, Marder VJ, et al, eds. Hemostasis and Thrombosis. Basic Principles and Clinical Practice. Philadelphia, Pa: Lippincott Williams & Wilkins; 2001:1003-20.

  83. Ahmad F, Solymoss S, Poon MC, Berube C, Sullivan AK. Characterization of an acquired IgG inhibitor of coagulation factor XIII in a patient with systemic lupus erythematosus. Br J Haematol. Jun 1996;93(3):700-3. [Medline].

  84. Tosetto A, Rodeghiero F, Gatto E, Manotti C, Poli T. An acquired hemorrhagic disorder of fibrin crosslinking due to IgG antibodies to FXIII, successfully treated with FXIII replacement and cyclophosphamide. Am J Hematol. Jan 1995;48(1):34-9. [Medline].

  85. Krumdieck R, Shaw DR, Huang ST, Poon MC, Rustagi PK. Hemorrhagic disorder due to an isoniazid-associated acquired factor XIII inhibitor in a patient with Waldenstrom's macroglobulinemia. Am J Med. May 1991;90(5):639-45. [Medline].

  86. Heinle K, Adam O, Rauh G. Factor XIII insufficiency in a patient with severe psoriasis vulgaris, arthritis, and infirmity. Clin Rheumatol. 1998;17(4):346-8. [Medline].

  87. Lorand L. Acquired inhibitors of fibrin stabilization: a class of hemorrhagic disorders of diverse origins. In: Anticoagulants: Physiologic, Pathologic and Pharmacologic. CRC Press; 1994:169-91.

  88. McKenna R. Abnormal coagulation in the postoperative period contributing to excessive bleeding. Med Clin North Am. Sep 2001;85(5):1277-310, viii. [Medline].

  89. Glidden PF, Malaska C, Herring SW. Thromboelastograph assay for measuring the mechanical strength of fibrin sealant clots. Clin Appl Thromb Hemost. Oct 2000;6(4):226-33. [Medline].

  90. Karpati L, Penke B, Katona E, Balogh I, Vamosi G, Muszbek L. A modified, optimized kinetic photometric assay for the determination of blood coagulation factor XIII activity in plasma. Clin Chem. Dec 2000;46(12):1946-55. [Medline].

  91. Katona E, Haramura G, Karpati L, Fachet J, Muszbek L. A simple, quick one-step ELISA assay for the determination of complex plasma factor XIII (A2B2). Thromb Haemost. Feb 2000;83(2):268-73. [Medline].

  92. Killick CJ, Barton CJ, Aslam S, Standen G. Prenatal diagnosis in factor XIII-A deficiency. Arch Dis Child Fetal Neonatal Ed. May 1999;80(3):F238-9. [Medline]. [Full Text].

  93. Orosz ZZ, Katona E, Facsko A, Berta A, Muszbek L. A highly sensitive chemiluminescence immunoassay for the measurement of coagulation factor XIII subunits and their complex in tears. J Immunol Methods. Feb 28 2010;353(1-2):87-92. [Medline].

  94. Gootenberg JE. Factor concentrates for the treatment of factor XIII deficiency. Curr Opin Hematol. Nov 1998;5(6):372-5. [Medline].

  95. Green D. Spontaneous inhibitors to coagulation factors. Clin Lab Haematol. Oct 2000;22 Suppl 1:21-5; discussion 30-2. [Medline].

  96. Lorand L, Losowsky MS, Miloszewski KJM. Human factor XIII: fibrin stabilizing factor. In: Spaet T, ed. Progress in Hemostasis and Thrombosis. Vol 5. New York, NY: Grune & Stratton; 1980:245-90.

  97. Abbondanzo SL, Gootenberg JE, Lofts RS, McPherson RA. Intracranial hemorrhage in congenital deficiency of factor XIII. Am J Pediatr Hematol Oncol. Spring 1988;10(1):65-8. [Medline].

  98. Green D, Sanders J, Wong C, et al. Coronary revascularization in the presence of an inhibitory antibody to factor XIII. Bull Intensive Crit Care. 1996;3(3):14-6.

  99. Wiel E, Marciniak B, Wibaut B. [Recurrent hematomas and normal standard hemostasis tests]. Ann Fr Anesth Reanim. 1998;17(1):61-4. [Medline].

  100. Kawamura A, Tamaki N, Yonezawa K, Nakamura M, Asada M. [Effect of factor XIII on intractable CSF leakage after a transpetrosal-approach operation: a case report]. No Shinkei Geka. Jan 1997;25(1):53-6. [Medline].

  101. Chamouard P, Grunebaum L, Wiesel ML, et al. Significance of diminished factor XIII in Crohn's disease. Am J Gastroenterol. Apr 1998;93(4):610-4. [Medline].

  102. Linskens RK, van Bodegraven AA, Schoorl M, Tuynman HA, Bartels P. Predictive value of inflammatory and coagulation parameters in the course of severe ulcerative colitis. Dig Dis Sci. Mar 2001;46(3):644-8. [Medline].

  103. Helio T, Wartiovaara U, Halme L, et al. Arg506Gln factor V mutation and Val34Leu factor XIII polymorphism in Finnish patients with inflammatory bowel disease. Scand J Gastroenterol. Feb 1999;34(2):170-4. [Medline].

  104. Burrows RF, Ray JG, Burrows EA. Bleeding risk and reproductive capacity among patients with factor XIII deficiency: a case presentation and review of the literature. Obstet Gynecol Surv. Feb 2000;55(2):103-8. [Medline].

  105. Kreilgaard L, Jones LS, Randolph TW, et al. Effect of Tween 20 on freeze-thawing- and agitation-induced aggregation of recombinant human factor XIII. J Pharm Sci. Dec 1998;87(12):1597-603. [Medline].

  106. Kreilgaard L, Frokjaer S, Flink JM, Randolph TW, Carpenter JF. Effects of additives on the stability of recombinant human factor XIII during freeze-drying and storage in the dried solid. Arch Biochem Biophys. Dec 1 1998;360(1):121-34. [Medline].

  107. Dickneite G, Metzner H, Nicolay U. Prevention of suture hole bleeding using fibrin sealant: benefits of factor XIII. J Surg Res. Oct 2000;93(2):201-5. [Medline].

  108. ARC. FDA-approved product circular for Pooled Plasma, Solvent-Detergent-Treated (PLAS+SD) manufactured by the American Red Cross and V.I. Technologies, Inc. 2000.

  109. ARC. PLAS+SD (pooled plasma, solvent-detergent treated). Monograph by the American Red Cross and V. I. Technologies, Inc. 1999;VIT-001A9/99.

  110. MediView Express. Recombinant therapy enhances safety and quality of life for hemophilia patients. Paper presented at: 53rd Annual Meeting of the National Hemophilia Foundation. November 16, 2001: Nashville, Tennessee.

  111. Rigas B, Hasan I, Rehman R, Donahue P, Wittkowski KM, Lebovics E. Effect on treatment outcome of coinfection with SEN viruses in patients with hepatitis C. Lancet. Dec 8 2001;358(9297):1961-2. [Medline].

  112. Azzi A, De Santis R, Morfini M, et al. TT virus contaminates first-generation recombinant factor VIII concentrates. Blood. Oct 15 2001;98(8):2571-3. [Medline].

  113. Bachmann F. Plasminogen-plasmin enzyme system. In: Colman RW, Hirsh J, George JN, et al, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 4th ed. Lippincott Williams & Wilkins; 2001:275-320.

  114. [Best Evidence] Fergusson DA, Hebert PC, Mazer CD, et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med. May 29 2008;358(22):2319-31. [Medline].

  115. Di Bisceglie AM. SEN and sensibility: interactions between newly discovered and other hepatitis viruses?. Lancet. Dec 8 2001;358(9297):1925-6. [Medline].

  116. Treisman GJ, Angelino AF, Hutton HE. Psychiatric issues in the management of patients with HIV infection. JAMA. Dec 12 2001;286(22):2857-64. [Medline].

  117. Senior K. New variant CJD fears threaten blood supplies. Lancet. Jul 28 2001;358(9278):304. [Medline].

  118. Krushkal J, Bat O, Gigli I. Evolutionary relationships among proteins encoded by the regulator of complement activation gene cluster. Mol Biol Evol. Nov 2000;17(11):1718-30. [Medline].

  119. Lorand L. Fibrin clots. Nature. Oct 21 1950;166(4225):694-5. [Medline].

  120. McKenna R. Factor VIII. eMedicine Journal [serial online]. 2001;Available at: http://emedicine.medscape.com/article/201319-overview. [Full Text].

  121. Mosesson MW, Siebenlist KR, Voskuilen M, Nieuwenhuizen W. Evaluation of the factors contributing to fibrin-dependent plasminogen activation. Thromb Haemost. Apr 1998;79(4):796-801. [Medline].

  122. Raghunath M, Meuli M. Cultured epithelial autografts: diving from surgery into matrix biology. Pediatr Surg Int. Sep 1997;12(7):478-83. [Medline].

  123. Robbins KC. A study of the conversion of fibrinogen to fibrin. Am J Physiol. 1944;142:581.

  124. Roberts HR, Monroe DM III, Hoffman M. Molecular biology and biochemistry of the coagulation factors and pathways of hemostasis. In: Beutler E, Lichtman M, Coller B, et al, eds. Williams Hematology. 6th ed. New York, NY: McGraw-Hill Professional; 2001:1409-34.

  125. Sugo T, Nakamikawa C, Takebe M, Kohno I, Egbring R, Matsuda M. Factor XIIIa cross-linking of the Marburg fibrin: formation of alpham.gamman-heteromultimers and the alpha-chain-linked albumin. gamma complex, and disturbed protofibril assembly resulting in acquisition of plasmin resistance relevant to thrombophila. Blood. May 1 1998;91(9):3282-8. [Medline].

 
Previous
Next
 
Coagulation reactions leading to thrombin generation and activation of factor XIII.
Final steps in clot formation (from article: Factor XIII).
Activation of factor XIII and generation of insoluble cross-linked fibrin. Adapted from Lorand L. Ann N Y Acad Sci. 2001;936:291-311.
Postulated interaction between factor XIII and thrombin-activatable fibrinolytic inhibitor.
Cell surfaced–directed hemostasis. Initially, a small amount of thrombin is generated on the surface of the tissue factor–bearing (TF-bearing) cell. Following amplification, the second burst generates a larger amount of thrombin, leading to fibrin (clot) formation (from article: Factor XIII). Adapted from Hoffman and Monroe. Thromb Haemost. 2001;85(6):958-65.
Gene, messenger RNA, and protein for subunit A of factor XIII. Adapted from Reitsma PH. In: Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Lippincott Williams & Wilkins; 2001:59-87 and from Roberts HR, Monroe DM III, Hoffman M. In: Williams Hematology. McGraw-Hill Professional; 2001:1409-34.
Table. Some Features of the A and B Chains of Factor XIII
Properties A ChainB Chain
Plasma FXIIIHas 2 A chainsHas 2 B chains
Plasma levelApproximately 15 mg/mLApproximately 21 mg/mL
Chains are free in plasmaNo. All bound to B chain and present as an A2 B2 tetramerYes. Excess B chain present in plasma as a B2 dimer
Chain contains the catalytic siteYesNo
Chain is the carrier proteinNoYes
Chain acts as a brake on FXIII activationNoYes
Cellular FXIIIHas 2 A chains (A2 dimer)Has no B chains
Mutations can lead to decreased FXIII activityYesYes
Previous
Next
 
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.